Detalhe da pesquisa
1.
Minimal residual disease predicts outcomes in KMT2A-rearranged but not KMT2A-germline infant acute lymphoblastic leukemia: Report from Children's Oncology Group study AALL0631.
Pediatr Blood Cancer
; : e30467, 2023 May 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-37259259
2.
Pulmonary toxicity in paediatric patients with relapsed or refractory Hodgkin lymphoma receiving brentuximab vedotin.
Br J Haematol
; 183(2): 251-256, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30198571
3.
Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy.
Leukemia
; 37(1): 61-71, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36380143
4.
Assessment of enrollment characteristics for Children's Oncology Group (COG) upfront therapeutic clinical trials 2004-2015.
PLoS One
; 15(4): e0230824, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32324751
5.
The safety of SARS-CoV-2 vaccines in persons with a known history of pegaspargase allergy: A single institution experience.
J Allergy Clin Immunol Pract
; 10(2): 630-632, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34883262